NEUROCRINE BIOSCIENCES, INC.
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 1992-01-01
- Employees
- 1.4K
- Market Cap
- $15.4B
- Website
- http://www.neurocrine.com
Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 7
- Registration Number
- NCT06312189
- Locations
- 🇨🇦
Neurocrine Clinical Site, Toronto, Ontario, Canada
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 72
- Registration Number
- NCT06267846
- Locations
- 🇺🇸
Neurocrine Clinical Site, Richardson, Texas, United States
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
- Conditions
- Interventions
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 59
- Registration Number
- NCT05859698
- Locations
- 🇺🇸
Neurocrine Clinical Site, Houston, Texas, United States
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 8
- Registration Number
- NCT05654870
- Locations
- 🇺🇸
Neurocrine Clinical Site, Atlanta, Georgia, United States
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 213
- Registration Number
- NCT05545111
- Locations
- 🇺🇸
Neurocrine Clinical site, Saint Louis, Missouri, United States
🇺🇸Neurocrine Clinical Site, Richardson, Texas, United States
Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 82
- Registration Number
- NCT05493293
- Locations
- 🇪🇸
Neurocrine Clinical Site, Valencia, Spain
Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 24
- Registration Number
- NCT05301894
- Locations
- 🇬🇧
Neurocrine Clinical Site, London, United Kingdom
Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE
- Conditions
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 52
- Registration Number
- NCT05226780
- Locations
- 🇺🇸
UCSF Medical Center, San Francisco, California, United States
🇺🇸Cook Children's Medical Center, Fort Worth, Texas, United States
🇺🇸University of Rochester, Rochester, New York, United States
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 80
- Registration Number
- NCT05206513
- Locations
- 🇪🇸
Neurocrine Clinical Site, San Sebastián, Spain
🇦🇷Neurocrine Clincial Site, Ciudad Autónoma de Buenos Aires, Argentina
Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 183
- Registration Number
- NCT05203341
- Locations
- 🇸🇪
Neurocrine Clinical Site, Stockholm, Sweden